BiotechTube
LightOx

LightOx

Newcastle, United Kingdom· Est.
lightox.co.uk
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.5M

Overview

LightOx, founded in 2016 and based in Newcastle, UK, is advancing a platform of light-activated small-molecule drugs. Its lead candidate, LXD191, is a topical gel for early-stage oral cancer, with plans to enter a Phase I/IIa clinical trial in 2025. The company has a strong IP position with five global patents, has secured strategic partnerships, and is exploring platform expansion into anti-fibrotic and non-oncology applications.

OncologyFibrotic Diseases

Technology Platform

Platform of novel small-molecule photosensitizing agents with intrinsic light-activated cell-killing properties. Compounds are designed for selective uptake, minimal off-target toxicity, and can be used as standalone therapeutics, linked to targeting moieties (e.g., antibodies for ADCs), or as theranostic agents.

Funding History

3
Total raised:$7.5M
Series A$5.2M
Grant$800K
Seed$1.5M

Opportunities

The primary opportunity is addressing the unmet need for a non-surgical, tissue-preserving treatment for early-stage oral cancer, a sizable market with high morbidity current care.
The platform's versatility allows expansion into other localized cancers, fibrotic diseases, and non-clinical areas like anti-infectives, creating multiple value drivers.

Risk Factors

Key risks include clinical trial failure for the lead candidate LXD191, regulatory hurdles for a novel drug-device combination, and competition from surgery and other light-based therapies.
Successful market adoption will require convincing clinicians to adopt a new treatment paradigm.

Competitive Landscape

LightOx competes in the photodynamic therapy (PDT) and targeted oncology space. It differentiates itself through its novel small-molecule chemistry designed for superior potency, selectivity, and formulation (topical gel). Competitors include other PDT drug developers and companies focused on non-invasive surgical alternatives for early-stage cancers.

More companies in United Kingdom →